<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574301</url>
  </required_header>
  <id_info>
    <org_study_id>UAMS 07050</org_study_id>
    <secondary_id>NIH Grant 5 R21 CA097715-01</secondary_id>
    <nct_id>NCT00574301</nct_id>
  </id_info>
  <brief_title>Percutaneous Removal and Margin Ablation for Breast Cancer</brief_title>
  <official_title>Percutaneous Removal and Margin Ablation for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ethicon Endo-Surgery</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>RITA Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that radiofrequency ablation after single-insertion image guided vacuum
      assisted biopsy (IVEB) can be used to achieve negative margins in small unicentric breast
      cancers (≤1.5 cm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using the Mammotome Breast Biopsy System (IVEB) in conjunction with MRI to predict extent of
      disease, ultrasound to direct removal of the tumor, touch preparation cytology for diagnosis,
      and ablation of margins using radiofrequency ablation (RFA), we propose to develop a
      comprehensive system for same-day diagnosis and treatment of patients with small breast
      lesions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To quantify the degree of tumor-free margin achieved with image-guided vacuum assisted biopsy followed by ablation with radiofrequency ablation</measure>
    <time_frame>Post-surgical pathology review</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with viable tumor cells beyond the margin</measure>
    <time_frame>Post-surgical pathology review</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Removal and Margin Ablation</intervention_name>
    <description>Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mammotome Breast Biopsy System (IVEB), Ethicon Endo-Surgery</other_name>
    <other_name>Radiofrequency Ablation (RFA), RITA Medical Systems</other_name>
    <other_name>Lumpectomy</other_name>
    <other_name>Mastectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, 18 to 90 years of age

          -  Non-pregnant, not breastfeeding

          -  Pre-study documentation of:

          -  Size ≤1.5 cm cancer successfully removed by US-guided IVEB within 30 days of
             registration

          -  Uni-centricity, unilateral cancer by radiology (mammogram and MRI)

          -  Location of abnormality &gt; 1 cm from the skin

          -  Ductal Carcinoma, Invasive (Grade I-III) or In-Situ

          -  No palpable axillary or supraclavicular lymph nodes

          -  Good general health

          -  Zubrod Performance Status of 0, 1, or 2

          -  If prior non-breast malignancy, must have 5 year disease-free survival

          -  No prior chemotherapy

          -  Hormonal therapy must be stopped

          -  Therapy with tamoxifen must have been of 14 days or less duration

        Exclusion Criteria:

          -  Subjects less than 18 years of age or greater than 90 years of age

          -  Pregnant or breastfeeding

          -  Male

          -  Prior Breast Biopsy affected breast

          -  Breast implants

          -  Multicentric disease, bilateral disease

          -  Residual disease after IVEB of &gt; 1cm on MRI

          -  Lesions &gt; 1.5 cm in diameter

          -  Lesions &lt; 1 cm from skin surface

          -  Previous radiation therapy to the breast
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>V. Suzanne Klimberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas For Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Johnson AT, Henry-Tillman RS, Smith LF, Harshfield D, Korourian S, Brown H, Lane S, Colvert M, Klimberg VS. Percutaneous excisional breast biopsy. Am J Surg. 2002 Dec;184(6):550-4; discussion 554.</citation>
    <PMID>12488164</PMID>
  </reference>
  <results_reference>
    <citation>Klimberg VS, Boneti C, Adkins LL, Smith M, Siegel E, Zharov V, Ferguson S, Henry-Tillman R, Badgwell B, Korourian S. Feasibility of percutaneous excision followed by ablation for local control in breast cancer. Ann Surg Oncol. 2011 Oct;18(11):3079-87. doi: 10.1245/s10434-011-2002-y. Epub 2011 Sep 9.</citation>
    <PMID>21904959</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2007</study_first_posted>
  <last_update_submitted>July 24, 2013</last_update_submitted>
  <last_update_submitted_qc>July 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Image Guided Vacuum Assisted Biopsy</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <keyword>Breast Conservation Therapy</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

